LoginRegister

    Zydus gets USFDA nod for Omega-3-Acid Ethyl Esters capsules

    Farhat NasimWritten by Farhat Nasim   |  
    Zydus gets USFDA nod for Omega-3-Acid Ethyl Esters capsules

    Omega-3-acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of certain blood fat (triglyceride), the company said in a statement.


    New Delhi: Zydus Pharmaceuticals' US arm Nesher Pharmaceuticals Saturday said it has received final approval from the USFDA to market Omega-3-Acid Ethyl Esters Capsules USP (USRLD - Lovaza Capsules).


    Omega-3-acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of certain blood fat (triglyceride), the company said in a statement.


    Also Read: Lupin, Zydus Cadila recall products in US; includes BP drug Carvedilol







    The capsule may also raise good cholesterol (HDL) levels, it added. The drug will be manufactured at Nesher Pharmaceuticals' manufacturing facility located at St. Louis, Missouri, US.





    The group now has 267 approvals and has so far filed over 360 ANDAs (abbreviated new drug applications) since the commencement of the filing process in FY 2003-04.


    ANDA is an application for a US generic drug approval for an existing licensed medication or approved drug.


    Also Read: Zydus Cadila gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

    abbreviated new drug applicationsCadila HealthcarechemistryEsterfish oilHealthcareLovaza capsulesmanufacturing facilitymedicineMissouriOmegaOmega-3 fatty acidOmega-3-acid ethyl estersOrganic compoundsPharmaceutical industry in IndiaTTUnited Stateszydus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      sidekick